Clinical Trial Update: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) [Phase 3]

View source ↗

Summary

A Phase 3 trial of Upifitamab Rilsodotin (Upifitamab Rilsodotin) in maintenance therapy for platinum-sensitive recurrent ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Upifitamab Rilsodotin (upifitamab rilsodotin)

Snippet

Sponsor: Mersana Therapeutics | Conditions: High Grade Serous Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Status: TERMINATED